ANTIEMETIC EFFECTS OF YM060, A POTENT AND SELECTIVE SEROTONIN (5HT)3-RECEPTOR ANTAGONIST, IN FERRETS AND DOGS

被引:26
作者
KAMATO, T
MIYATA, K
ITO, H
YUKI, H
YAMANO, M
HONDA, K
机构
[1] Medicinal Research Laboratories I, Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Tsukuba
关键词
D O I
10.1254/jjp.57.387
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
YM060, (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride, is a new serotonin (5HT)3-receptor antagonist. We examined the effects of YM060 on chemotherapeutic agent-, apomorphine- and copper sulfate-induced emesis. Intravenous YM060 potently prevented cisplatin (10 mg/kg, i.v.)-induced emesis with ED50 values of 0.06 (0.05-0.07)-mu-g/kg, i.v. in ferrets. Based on the ED50 values, YM060 was 300, 20 and 100 times more potent than ondansetron, granisetron and the S-isomer of YM060, respectively. The relative potencies of these drugs described above were similar to those in the previously reported 5HT3-receptor antagonism. YM060 given orally also potently inhibited cisplatin (10 mg/kg, i.p.)- and cyclophosphamide (200 mg/kg, i.p.)-induced emesis in ferrets with ED50 values of 0.1 (0.09-0.11) and 0.02 (0.16-0.27)-mu-g/kg, p.o., respectively. All tested 5HT3-receptor antagonists including YM060 failed to prevent apomorphine (0.1 mg/kg, s.c.)-induced emesis in dogs and copper sulfate (1%, 10 ml, p.o.)-induced emesis in ferrets. Our data indicate that YM060 is a highly potent inhibitor of chemotherapeutic agent-induced emesis and that the antiemetic effect of YM060 may be depend on 5HT3-receptor antagonism.
引用
收藏
页码:387 / 395
页数:9
相关论文
共 21 条
[11]  
HONDA K, 1991, JAPAN J PHARM S1, V55, pP365
[12]  
ITO H, 1991, JAPAN J PHARM S1, V55, pP364
[13]   5-HT3 RECEPTORS [J].
KILPATRICK, GJ ;
BUNCE, KT ;
TYERS, MB .
MEDICINAL RESEARCH REVIEWS, 1990, 10 (04) :441-475
[14]   DOSE-RANGING EVALUATION OF THE SEROTONIN ANTAGONIST GR-C507/75 (GR38032F) WHEN USED AS AN ANTIEMETIC IN PATIENTS RECEIVING ANTICANCER CHEMOTHERAPY [J].
KRIS, MG ;
GRALLA, RJ ;
CLARK, RA ;
TYSON, LB .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :659-662
[15]   PHASE-II TRIALS OF THE SEROTONIN ANTAGONIST GR38032F FOR THE CONTROL OF VOMITING CAUSED BY CISPLATIN [J].
KRIS, MG ;
GRALLA, RJ ;
CLARK, RA ;
TYSON, LB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (01) :42-46
[17]   INHIBITION OF CISPLATIN-INDUCED VOMITING BY SELECTIVE 5-HYDROXYTRYPTAMINE M-RECEPTOR ANTAGONISM [J].
MINER, WD ;
SANGER, GJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 88 (03) :497-499
[18]  
MIYATA K, 1991, JPN J PHARM S, V55, pP364
[19]   THE PHARMACOLOGY AND FUNCTION OF 5-HT3 RECEPTORS [J].
RICHARDSON, BP ;
ENGEL, G .
TRENDS IN NEUROSCIENCES, 1986, 9 (09) :424-428
[20]  
SMITH W L, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P260